Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Sell
50
SPRO Quote, Financials, Valuation and Earnings
Last price:
$2.56
Seasonality move
:
17.06%
Day range:
$2.52 - $2.57
52-week range:
$0.51 - $3.22
Dividend yield:
0%
P/E ratio:
10.75x
P/S ratio:
4.87x
P/B ratio:
5.47x
Volume:
284.6K
Avg. volume:
271.4K
1-year change:
155%
Market cap:
$144.8M
Revenue:
$27.4M
EPS (TTM):
-$0.79
Analysts' Opinion
-
Consensus RatingSpero Therapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.00, Spero Therapeutics, Inc. has an estimated upside of 55.64% from its current price of $2.55.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $2.55.
Fair Value
-
According to the consensus of 1 analyst, Spero Therapeutics, Inc. has 55.64% upside to fair value with a price target of $4.00 per share.
SPRO vs. S&P 500
-
Over the past 5 trading days, Spero Therapeutics, Inc. has overperformed the S&P 500 by 9.3% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Spero Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Spero Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Spero Therapeutics, Inc. reported revenues of $3M.
Earnings Growth
-
Spero Therapeutics, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Spero Therapeutics, Inc. reported earnings per share of -$0.13.
Enterprise value:
99.5M
EV / Invested capital:
--
Price / LTM sales:
4.87x
EV / EBIT:
0.54x
EV / Revenue:
3.39x
PEG ratio (5yr expected):
0.02x
EV / Free cash flow:
-3.60x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
0.54x
Gross Profit (TTM):
--
Return On Assets:
-49.85%
Net Income Margin (TTM):
-149.52%
Return On Equity:
-107.04%
Return On Invested Capital:
-97.58%
Operating Margin:
-319%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $71.3M | $89.9M | $29.3M | $7.8M | $3M | |
| Gross Profit | $70.1M | $77.8M | -- | -- | -- | |
| Operating Income | -$4.3M | -$17.7M | -$56.3M | -$24.2M | -$9.7M | |
| EBITDA | -$3.2M | -$17.7M | -$56.3M | -$24.2M | -$9.7M | |
| Diluted EPS | $0.01 | $0.08 | -$0.79 | -$0.32 | -$0.13 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $131.8M | $52.9M | $102.2M | $131.6M | $52.3M | |
| Total Assets | $144.7M | $64.5M | $107.1M | $135.2M | $54.2M | |
| Current Liabilities | $17.3M | $16.2M | $25.5M | $49.1M | $13.6M | |
| Total Liabilities | $32.8M | $32M | $53.4M | $69.7M | $27.7M | |
| Total Equity | $111.9M | $32.5M | $53.7M | $65.5M | $26.5M | |
| Total Debt | $7.2M | $5.2M | $4.1M | $2.9M | $1.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $29M | -$17.5M | -$27.7M | $12.8M | $17.4M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $14.4M | $1K | -- | -- | -- | |
| Free Cash Flow | $29M | -$17.5M | -$27.7M | $12.8M | $17.4M | |
SPRO
Sector
Market Cap
$144.8M
$28.3M
Price % of 52-Week High
79.81%
51.99%
Dividend Yield
0%
0%
Shareholder Yield
0.3%
-1.59%
1-Year Price Total Return
157%
-17.41%
Beta (5-Year)
1.461
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.45
200-day SMA
Buy
Level
$1.98
Bollinger Bands (100)
Buy
Level
2.01 - 2.43
Chaikin Money Flow
Buy
Level
131.6K
20-day SMA
Buy
Level
$2.37
Relative Strength Index (RSI14)
Buy
Level
64.19
ADX Line
Buy
Level
52.36
Williams %R
Neutral
Level
-22.0779
50-day SMA
Buy
Level
$2.38
MACD (12, 26)
Buy
Level
0.60
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
640.9K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-7.1961)
Sell
CA Score
(Annual)
Level (-3.154)
Sell
Beneish M-Score
(Annual)
Level (10.8193)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.7027)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, SPRO has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The SPRO average analyst price target in the past 3 months is $4.00.
-
Where Will Spero Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Spero Therapeutics, Inc. share price will rise to $4.00 per share over the next 12 months.
-
What Do Analysts Say About Spero Therapeutics, Inc.?
Analysts are divided on their view about Spero Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Spero Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Spero Therapeutics, Inc.'s Price Target?
The price target for Spero Therapeutics, Inc. over the next 1-year time period is forecast to be $4.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is SPRO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Spero Therapeutics, Inc. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of SPRO?
You can purchase shares of Spero Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Spero Therapeutics, Inc. shares.
-
What Is The Spero Therapeutics, Inc. Share Price Today?
Spero Therapeutics, Inc. was last trading at $2.56 per share. This represents the most recent stock quote for Spero Therapeutics, Inc.. Yesterday, Spero Therapeutics, Inc. closed at $2.55 per share.
-
How To Buy Spero Therapeutics, Inc. Stock Online?
In order to purchase Spero Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SPRO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SPRO
Sector
P/E ratio
10.75x
24.24x
PEG ratio
0.02x
-0.01x
P/B ratio
5.47x
1.84x
Price / LTM sales
4.87x
1.60x
Growth Metrics
SPRO
Sector
Revenue growth
-61.02%
4.6%
Earnings growth
58.59%
10.71%
Revenue (5-year growth)
8.59%
6.45%
Earnings forecast
-$0.32
-$0.19
Profitability
SPRO
Sector
Profitability FY 2024
$27.4M
$3.5M
Return on invested capital
-97.58%
-32.04%
Return on assets
-49.85%
-28.44%
Return on equity
-107.04%
-38.09%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
12
Balance Sheet
SPRO
Sector
Total cash
$48.6M
$26.1M
Short term investments
--
$25.7M
Total assets
$110.5M
$76.4M
Long term debt
$1.5M
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
